Illumina (NASDAQ:ILMN) had its target price hoisted by equities researchers at Morgan Stanley from $122.00 to $135.00 in a research note issued on Thursday. The brokerage currently has an “underweight” rating on the life sciences company’s stock. Morgan Stanley’s price target points to a potential downside of 37.20% from the stock’s current price.

Other analysts have also issued research reports about the stock. Wells Fargo & Company reaffirmed a “market perform” rating and set a $205.00 target price (up previously from $200.00) on shares of Illumina in a report on Wednesday, October 25th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $252.00 price target for the company in a research note on Tuesday, December 5th. Bank of America boosted their price target on shares of Illumina from $215.00 to $240.00 and gave the stock a “buy” rating in a research note on Wednesday, October 25th. BidaskClub cut shares of Illumina from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. Finally, Vetr raised shares of Illumina from a “hold” rating to a “buy” rating and set a $217.50 price target for the company in a research note on Tuesday, September 19th. One analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $202.60.

Illumina (ILMN) traded up $0.42 during trading on Thursday, reaching $214.97. 83,066 shares of the company were exchanged, compared to its average volume of 951,530. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. The company has a market cap of $31,045.44, a price-to-earnings ratio of 62.17, a PEG ratio of 3.51 and a beta of 0.79. Illumina has a twelve month low of $124.82 and a twelve month high of $230.72.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. The business had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. Illumina’s revenue was up 17.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.97 EPS. research analysts anticipate that Illumina will post 3.75 earnings per share for the current year.

In other Illumina news, SVP Charles Dadswell sold 145 shares of the stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $202.23, for a total transaction of $29,323.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert S. Epstein sold 1,250 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $226.55, for a total transaction of $283,187.50. Following the sale, the director now directly owns 9,088 shares of the company’s stock, valued at approximately $2,058,886.40. The disclosure for this sale can be found here. Insiders sold a total of 136,421 shares of company stock valued at $28,489,101 in the last ninety days. 0.89% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in Illumina by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock valued at $1,718,601,000 after buying an additional 255,498 shares during the period. Ameriprise Financial Inc. raised its holdings in Illumina by 3.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,512,167 shares of the life sciences company’s stock worth $500,416,000 after purchasing an additional 76,452 shares in the last quarter. Capital World Investors raised its holdings in Illumina by 23.8% in the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after purchasing an additional 410,000 shares in the last quarter. TIAA CREF Investment Management LLC raised its holdings in Illumina by 55.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after purchasing an additional 527,548 shares in the last quarter. Finally, Winslow Capital Management LLC bought a new position in Illumina in the 2nd quarter worth $211,584,000. 91.75% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/12/14/morgan-stanley-increases-illumina-ilmn-price-target-to-135-00.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Stock Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related stocks with our FREE daily email newsletter.